1. Home
  2. NEO vs AKBA Comparison

NEO vs AKBA Comparison

Compare NEO & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NEO
  • AKBA
  • Stock Information
  • Founded
  • NEO 2001
  • AKBA 2007
  • Country
  • NEO United States
  • AKBA United States
  • Employees
  • NEO N/A
  • AKBA N/A
  • Industry
  • NEO Precision Instruments
  • AKBA Biotechnology: Pharmaceutical Preparations
  • Sector
  • NEO Health Care
  • AKBA Health Care
  • Exchange
  • NEO Nasdaq
  • AKBA Nasdaq
  • Market Cap
  • NEO 1.0B
  • AKBA 861.7M
  • IPO Year
  • NEO 1999
  • AKBA 2014
  • Fundamental
  • Price
  • NEO $8.34
  • AKBA $2.99
  • Analyst Decision
  • NEO Buy
  • AKBA Strong Buy
  • Analyst Count
  • NEO 9
  • AKBA 5
  • Target Price
  • NEO $12.63
  • AKBA $6.90
  • AVG Volume (30 Days)
  • NEO 2.7M
  • AKBA 3.9M
  • Earning Date
  • NEO 11-04-2025
  • AKBA 11-06-2025
  • Dividend Yield
  • NEO N/A
  • AKBA N/A
  • EPS Growth
  • NEO N/A
  • AKBA N/A
  • EPS
  • NEO N/A
  • AKBA N/A
  • Revenue
  • NEO $689,189,000.00
  • AKBA $203,733,000.00
  • Revenue This Year
  • NEO $10.40
  • AKBA $38.23
  • Revenue Next Year
  • NEO $10.11
  • AKBA $38.17
  • P/E Ratio
  • NEO N/A
  • AKBA N/A
  • Revenue Growth
  • NEO 9.70
  • AKBA 16.75
  • 52 Week Low
  • NEO $4.72
  • AKBA $1.24
  • 52 Week High
  • NEO $19.12
  • AKBA $4.08
  • Technical
  • Relative Strength Index (RSI)
  • NEO 64.46
  • AKBA 41.58
  • Support Level
  • NEO $7.36
  • AKBA $2.92
  • Resistance Level
  • NEO $8.29
  • AKBA $3.15
  • Average True Range (ATR)
  • NEO 0.45
  • AKBA 0.15
  • MACD
  • NEO 0.06
  • AKBA 0.01
  • Stochastic Oscillator
  • NEO 74.47
  • AKBA 21.43

About NEO NeoGenomics Inc.

NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: